WO1991008246A2 - Polyesters for use in blood partitioning compositions - Google Patents
Polyesters for use in blood partitioning compositions Download PDFInfo
- Publication number
- WO1991008246A2 WO1991008246A2 PCT/US1990/006967 US9006967W WO9108246A2 WO 1991008246 A2 WO1991008246 A2 WO 1991008246A2 US 9006967 W US9006967 W US 9006967W WO 9108246 A2 WO9108246 A2 WO 9108246A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- polyester
- mixture
- accordance
- group
- Prior art date
Links
- 229920000728 polyester Polymers 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 210000004369 blood Anatomy 0.000 title abstract description 42
- 239000008280 blood Substances 0.000 title abstract description 42
- 238000000638 solvent extraction Methods 0.000 title abstract description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 58
- 239000002253 acid Substances 0.000 claims description 53
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 32
- 150000002009 diols Chemical class 0.000 claims description 21
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 claims description 14
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 12
- 150000007513 acids Chemical class 0.000 claims description 10
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 150000001991 dicarboxylic acids Chemical class 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 150000004665 fatty acids Chemical class 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 8
- UDSFAEKRVUSQDD-UHFFFAOYSA-N Dimethyl adipate Chemical compound COC(=O)CCCCC(=O)OC UDSFAEKRVUSQDD-UHFFFAOYSA-N 0.000 claims description 6
- 235000011037 adipic acid Nutrition 0.000 claims description 6
- XTDYIOOONNVFMA-UHFFFAOYSA-N dimethyl pentanedioate Chemical compound COC(=O)CCCC(=O)OC XTDYIOOONNVFMA-UHFFFAOYSA-N 0.000 claims description 6
- MUXOBHXGJLMRAB-UHFFFAOYSA-N Dimethyl succinate Chemical compound COC(=O)CCC(=O)OC MUXOBHXGJLMRAB-UHFFFAOYSA-N 0.000 claims description 5
- 239000001361 adipic acid Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- QDCPNGVVOWVKJG-VAWYXSNFSA-N 2-[(e)-dodec-1-enyl]butanedioic acid Chemical compound CCCCCCCCCC\C=C\C(C(O)=O)CC(O)=O QDCPNGVVOWVKJG-VAWYXSNFSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 4
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 4
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 claims description 4
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims description 4
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 3
- 150000002763 monocarboxylic acids Chemical class 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- LWBHHRRTOZQPDM-UHFFFAOYSA-N undecanedioic acid Chemical compound OC(=O)CCCCCCCCCC(O)=O LWBHHRRTOZQPDM-UHFFFAOYSA-N 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 1
- 235000020778 linoleic acid Nutrition 0.000 claims 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 13
- 238000005119 centrifugation Methods 0.000 abstract description 7
- 230000005484 gravity Effects 0.000 abstract description 4
- 238000012544 monitoring process Methods 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 229940126585 therapeutic drug Drugs 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 description 28
- 239000000306 component Substances 0.000 description 24
- 229960004063 propylene glycol Drugs 0.000 description 16
- 235000013772 propylene glycol Nutrition 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 14
- 239000003054 catalyst Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 238000005886 esterification reaction Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000000376 reactant Substances 0.000 description 10
- 230000032050 esterification Effects 0.000 description 9
- ISKQADXMHQSTHK-UHFFFAOYSA-N [4-(aminomethyl)phenyl]methanamine Chemical compound NCC1=CC=C(CN)C=C1 ISKQADXMHQSTHK-UHFFFAOYSA-N 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WVRNUXJQQFPNMN-VAWYXSNFSA-N 3-[(e)-dodec-1-enyl]oxolane-2,5-dione Chemical compound CCCCCCCCCC\C=C\C1CC(=O)OC1=O WVRNUXJQQFPNMN-VAWYXSNFSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 229960004801 imipramine Drugs 0.000 description 3
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 239000000565 sealant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000005292 vacuum distillation Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- AMOKUAKXKXBFIW-WJDWOHSUSA-N 9-[(z)-non-3-enyl]-10-octylnonadecanedioic acid Chemical compound OC(=O)CCCCCCCCC(CCCCCCCC)C(CCCCCCCC(O)=O)CC\C=C/CCCCC AMOKUAKXKXBFIW-WJDWOHSUSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RGCVYEOTYJCNOS-UHFFFAOYSA-N (4-cyano-2-methylphenyl)boronic acid Chemical compound CC1=CC(C#N)=CC=C1B(O)O RGCVYEOTYJCNOS-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 229940083957 1,2-butanediol Drugs 0.000 description 1
- OQBLGYCUQGDOOR-UHFFFAOYSA-L 1,3,2$l^{2}-dioxastannolane-4,5-dione Chemical compound O=C1O[Sn]OC1=O OQBLGYCUQGDOOR-UHFFFAOYSA-L 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- 229920001634 Copolyester Polymers 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- DRUKNYVQGHETPO-UHFFFAOYSA-N Nonanedioic acid dimethyl ester Natural products COC(=O)CCCCCCCC(=O)OC DRUKNYVQGHETPO-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001279 adipic acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- YHWCPXVTRSHPNY-UHFFFAOYSA-N butan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCC[O-].CCCC[O-].CCCC[O-].CCCC[O-] YHWCPXVTRSHPNY-UHFFFAOYSA-N 0.000 description 1
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-M chlorite Chemical compound [O-]Cl=O QBWCMBCROVPCKQ-UHFFFAOYSA-M 0.000 description 1
- 229910001919 chlorite Inorganic materials 0.000 description 1
- 229910052619 chlorite group Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- -1 e.g. Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002311 glutaric acids Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- RUOPINZRYMFPBF-UHFFFAOYSA-N pentane-1,3-diol Chemical compound CCC(O)CCO RUOPINZRYMFPBF-UHFFFAOYSA-N 0.000 description 1
- GLOBUAZSRIOKLN-UHFFFAOYSA-N pentane-1,4-diol Chemical compound CC(O)CCCO GLOBUAZSRIOKLN-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229910021647 smectite Inorganic materials 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003784 tall oil Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/12—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
- C08G63/52—Polycarboxylic acids or polyhydroxy compounds in which at least one of the two components contains aliphatic unsaturation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/12—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
- C08G63/16—Dicarboxylic acids and dihydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/12—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
- C08G63/46—Polyesters chemically modified by esterification
- C08G63/48—Polyesters chemically modified by esterification by unsaturated higher fatty oils or their acids; by resin acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
Definitions
- the present invention relates to polyesters useful for facilitating the separation of blood serum 5 or plasma from the cellular portion of blood.
- the polyesters of the invention are conveniently formulated into a partitioning composition for use in a blood collection vessel in which the blood sample is subjected to centri ugation until the cellular portion 10 and serum or plasma are completely separated.
- the physical and chemical properties of the partitioning composition are such that a continuous, integral seal is provided between the separated blood phases, thereby maintaining separation of the phases after 15 centrifugation and simplifying removal of the serum or plasma from the blood collection vessel.
- Fluid sealant compositions are formulated to have a specific gravity intermediate the two blood phases sought to be separated, so as to provide a partition a the interface between the cellular and serum phases.
- Such compositions typically include a polymer base material, one or more additives for adjusting the specific gravity and viscosity of the resultant composition, and optionally, a network former.
- Representative prior art fluid sealant compositions include: styrene beads coated with an anti-coagulent (U.S. Patent 3,464,890); silicone fluid having silica dispersed therein (U.S. Patent 3,780,935); a homogenous, hydrophobic copolyester including a suitable filler, e.g., silica (U.S.
- Patents 4,101,422 and 4,148,764) a liquid -olefin-dialkylmaleate, together with an aliphatic amine derivative of smectite clay or powdered silica (U.S. Patent 4,310,430); the reaction product of a silicone fluid with a silica filler and a network former (U.S. Patent 4,386,003); and a mixture of compatible viscous liquids, e.g., epoxidized vegetable oil and chlorinated polybutene, and a thixotropy- imparting agent, e.g., powdered silica (U.S. Patent 4,534,798).
- a commercially useful blood partitioning composition should maintain uniform physical and chemical properties for extended time periods prior to use, as well as during transportation and processing of blood samples, readily form a stable partition under normal centrifugation conditions and be relatively inert or unreactive toward the substance(s) in the blood whose presence or concentration is to be determined.
- TDM therapeutic drug monitoring
- drugs recommended for administration under TDM are those having dangerous toxicity with poorly defined clinical endpoint, steep dose-response curve, narrow therapeutic range, considerable inter-individual pharmacokinetic variability or non-linear pharmacokinetics, as well as those used in long term therapy or in the treatment of life-threatening diseases.
- the evaluation of blood levels of a number of tricyclic antidepressant compounds, such as imipramine or desipra ine, in relation to an empirically established therapeutic range is reported to be particularly useful in the treatment of seemingly drug-refractive depression.
- TDM is likewise used to monitor the dosage of anticonvulsant drugs, such as phenytoin and phenobarbital which are administered in the treatment of epilepsy, antitumor drugs, such as methotrexate, and other more commonly prescribed drugs, including, but not limited to digoxin, lidocaine, pentobarbital and theophylline.
- anticonvulsant drugs such as phenytoin and phenobarbital which are administered in the treatment of epilepsy
- antitumor drugs such as methotrexate
- other more commonly prescribed drugs including, but not limited to digoxin, lidocaine, pentobarbital and theophylline.
- polyesters of the invention comprise, as their reactive components, at least one diol and at least one dicarboxylic acid, including a first dicarboxylic acid containing from 15-36 carbom atoms, which comprises from 10-100 equivalent percent of the total acid component equivalents, and a second dicarboxylic acid, selected from the group of short chain dicarboxylic acids and polymeric fatty acids, which comprises up to 90 equivalent percent of the total acid component equivalents.
- the resultant polyester product is a viscous liquid having a density at room temperature (25°C) in the range of 1.01-1.09.
- polyester products have been obtained from the reaction of dodecenylsuccinic acid with propylene glycol and from the reaction of linoleic acid-acrylic acid adduct, as the first dicarboxylic acid, and an acid selected from the group of succinic acid, glutaric, adipic acid, azelaic acid, oleic dimer acid, or a mixture thereof, as the second dicarboxylic acid, with a mixture of neopentyl glycol, and propylene glycol.
- the polyesters of the invention are readily formulated together with other ingredients, typically a suitable filler and compatible surfactant, into functional blood partitioning compositions.
- the density of the finished blood partitioning composition is controlled within prescribed limits, so that during centrifugation the composition becomes stably positioned at the interface between the serum or plasma phase and heavier cellular phase and, when centrifugation is terminated, forms a continuous integral barrier within the blood collection vessel to prevent the two phases from recombining or mixing, especially when decanting or pipetting the serum or plasma.
- the blood partitioning compositions of the invention are advantageously employed in small amounts, on the order of 1-5 gm. , in a 10 ml blood collection vessel of the type previously described which are then ready for use in blood sampling and analysis in the usual way.
- the polyester-based blood partitioning compositions of the invention are especially suited for use in TDM procedures, displaying negligible interaction with commonly monitored therapeutic agents.
- the present invention relates to polyesters derived from one or more relatively long-chain dicarboxylic acids, having 15-36 carbon atoms, optionally, a second dicarboxylic acid, selected from the group of short chain dicarboxylic acids and polymer fatty acids, and a diol.
- polyesters derived from one or more relatively long-chain dicarboxylic acids, having 15-36 carbon atoms, optionally, a second dicarboxylic acid, selected from the group of short chain dicarboxylic acids and polymer fatty acids, and a diol.
- polyester products are obtained having molecular weights from about 3,000 to about 12,000 (number average, as determined by gel permeation chromatography) .
- the polyesters of the invention are produced in the form of viscous liquids, having a density at room temperature in the range of 1.01-1.09.
- polyesters of the invention are also highly hydrophobic, exhibiting neglible water solubility.
- the physical and chemical properties of these polyesters are uniformly maintained over extended periods prior to use, as well as during transportation and processing of blood samples.
- G being the ratio of centrifugal acceleration to acceleration of gravity
- polyesters of the invention are further characterized by having an acid value of 2 or less, an hydroxyl value of 23 or less and a 210°F kinematic viscosity of about 1700-4000 centistokes. _ ? _
- Polyesters having the above-described properties are especially useful as blood partitioning agents in blood collection vessels where they provide a continuous integral barrier or seal between the serum and clot portions of blood.
- the polyester completely partitions the separated phases so that the serum and cellular or clot portions are no longer in contact at any point, forming a unitary seal which firmly adheres to the inner surface of the blood collection vessel.
- the reactive components of the polyesters of the invention include at least one dicarboxylic acid, including a first dicarboxylic acid containing 15-36 carbon atoms, a second dicarboxylic acid, selected from the group of short-chain dicarboxylic acids and polymeric fatty acids, and at least one diol.
- the first dicarboxylic acid is preferably selected from the group of polyalkenylsuccinic acids, adducts of unsaturated monocarboxylic acids or a mixture thereof.
- the first dicarboxylic acid may be the exclusive constituent of the acid component of the polyester.
- the second dicarboxylic acid may optionally be added to the acid component.
- Short-chain dicarboxylic acids suitable for preparing the polyesters of the invention are saturated aliphatic acids having 4-12 carbon atoms. More preferably, these acids have from 4-9 carbon atoms and are essentially straight-chain acids.
- Representative short chain dicarboxylic acids include succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, undecanedoic acid and dodecanedoic acid.
- two or more of such short-chain dicarboxylic acids may be used, if desired.
- the polymeric fatty acids which may be used to prepare the polyesters of the invention are obtained by the polymerization of olefinically unsaturated monocarboxylic acids having from 16-20 carbon atoms, such as pal itoleic acid, oleic acid, linoleic acid, linolenic acid and the like.
- Polymeric fatty acids and processes for their production are well known. See, for example, U.S. Patent Nos. 2,793,219 and 2,955,121.
- Polymeric fatty acids useful in the practice of this invention preferably will have as their principal component C-36 dimer acid.
- Such C-36 dicarboxylic acids are obtained by the dimerization of two moles of a C-18 unsaturated monocarboxylic acid, such as oleic acid or linoleic acid, or mixtures thereof, e.g., tall oil fatty acids. These products typically contain 75% by weight or more of C-36 dimer acid and have an acid value in the range of 180-215, saponification value in the range of 190-215 and neutral equivalent from 265-310.
- the dimer acids may be hydrogenated prior to use.
- the polymeric fatty acid may be molecularly distilled or otherwise fractionated.
- the first dicarboxylic acid comprises from 10-100 equivalent percent of the total acid component equivalents; whereas the second dicarboxylic acid, when used, may comprise up to 90 equivalent percent of the total acid component equivalents.
- the equivalent percent of short-chain dicarboxylic acid(s) in the second dicarboxylic acid component will generally range from about 80 to about 100 equivalent percent of the total acid components provided by the second dicarboxylic acid.
- the polymeric fatty acid when used, will generally comprise up to about 20 6 . Q .
- the term "acid” is intended to encompass such acid derivatives.
- Methyl esters are particularly advantageous for the preparation of the polyesters described herein.
- Mixtures of acids, anhydrides and esters may also be reacted to obtain the desired product.
- Suitable diols which may be reacted with the above-described dicarboxylic acid(s) to yield the polyesters of the invention include diols of the formula:
- Representative diols falling within the foregoing formula include neopentyl glycol, propylene glycol, diethylene glycol, triethylene glycol, 3-methyl-l,5- pentane diol, 1,2 propane diol, 1,3-butane diol, 1,2-butane diol, 1,2-pentane diol, 1,3-pentane diol, 1,4-pentane diol and the like.
- the preferred diols contain from 3-5 carbon atoms, with particularly useful polyesters products being obtained using neopentyl glycol, propylene glycol, triethylene glycol, or mixtures thereof.
- the amount of neopentyl glycol comprises about 70 to about 95 equivalent percent
- the amount of propylene glycol comprises about 5 to about 30 equivalent percent of the total diol component equivalents.
- the reactive components are normally added to the reaction vessel as a unit charge and the reaction mixture is then heated with agitation at a temperature from about 150-250°C for a period of time sufficient to substantially complete the esterification reaction.
- the reaction may be driven to completion by application of vacuum (typically 1-5 mm Hg absolute at 200-250°C) until the desired properties are obtained. Vacuum distillation removes the final traces of water, any excess reactants and small amounts of other volatile materials present in the reaction mixture.
- the polyester may be bleached by any of the well known and acceptable bleaching methods, e.g., using hydrogen peroxide or chlorite.
- the polyester may be decolorized by filtering through a filter aid, charcoal or bleaching clay.
- the rate of esterification may be enhanced by the use of known esterification catalysts.
- Suitable esterification catalysts for enhancing the rate of esterification of free carboxyl groups include phosphoric acid, sulfuric acid, toluenesulfonic acid, methane sulfonic acid, and the like. The amount of such catalyst may vary widely, but most often will be in an amount from about 0.1% to about 0.5% by weight, based on the total reactant charge.
- Catalysts useful for effecting ester interchange include dibutyltin diacetate, stannous oxalate, dibutyltin oxide, tetrabutyl titanate, zinc acetate and the like.
- catalysts are generally employed in an amount ranging from about .01% to .05% by weight, based on the total resistant charge. When such catalysts are used, it is not necessary that the catalyst be present throughout the entire reaction. It is sometimes advantageous in order to obtain products having good color and relatively low acid value, on the order of 2 mg KOH/gm, or less, to add the catalyst during the final stages of the reaction. Upon completion of the reaction, the catalyst may be deactivated and removed by filtering or other conventional means.
- Inert diluents such as benzene, toluene, xylene and the like may be employed for the reaction, however, the use of diluents is not necessary. It is generally considered desirable to conduct the reaction without diluents since the resultant polyester can be directly used as it is obtained from the reaction vessel.
- a small excess (based on the equivalents of acid present) of the diol component may be used if desired.
- the excess diol serves as the reaction medium and reduces the viscosity of the reaction mixture.
- the excess diol is distilled off as the esterification is carried to completion and may be recycled to the reactor if desired. Generally, about 20% by weight excess diol, based on the total weight of the diol component, will suffice. The more volatile glycols are commonly used for this purpose.
- a particularly useful blood partitioning agent is obtained by reacting substantially stoichiometric amounts of (i) linoleic acid-acrylic acid adduct, having 21 carbon atoms, as the first dicarboxylic acid component, a second dicarboxylic acid comprising (ii) oleic dimer acid and (iii) a mixture of dimethyl succinate, dimethyl glutarate, and dimethyl adipate, with a diol component comprising neopentyl glycol and propylene glycol.
- the equivalents ratio of the three dicarboxylic acid components is 1:1:3.55, with the relative approximate weight percentages of the esters in the ester mixture being 1% dimethyl succinate, 75% dimethyl glutarate and 24% dimethyl adipate.
- the equivalents ratio of neopentyl glycol to propylene glycol ranges from about 0.75:0.25 to about 0.90:0.10.
- polyester product is obtained from the reaction of essentially stoichiometric amounts of dodecenylsuccinic acid and propylene glycol.
- dicarboxylic acid or acid derivative blends may be obtained by mixing the individual acid components.
- mixtures of acid obtained as by-products from various manufacturing operations and which contain one or more of the necessary acid components may be advantageously utilized.
- mixed dimethyl esters of succinic, glutaric and adipic acids may be obtained as a co-product from the manufacture of adipic acid and may be conveniently blended with any other acid, e.g., oleic dimer acid selected for inclusion in the polyester of the invention.
- Preparation of blood partitioning compositions using the polyesters of the invention may be carried out in the manner described in commonly owned U.S. Patents Nos. 4,101,422 and 4,148,764, the entire disclosures of which are incorporated by reference in the present specification, as if set forth herein in full.
- Determination of the extent of interaction between the polyesters of the invention and commonly monitored drugs may be carried out using well known recovery experiments and drug measurement techniques, such as, gas chromatography, gas-liquid chromatography, high-performance liquid chromatography, thin layer chromatography or immunoassay techniques, including radioimmunoassay, enzyme immunoassay, fluorescence polarization immunoassay, nephelometric assay, and the like.
- drug measurement techniques such as, gas chromatography, gas-liquid chromatography, high-performance liquid chromatography, thin layer chromatography or immunoassay techniques, including radioimmunoassay, enzyme immunoassay, fluorescence polarization immunoassay, nephelometric assay, and the like.
- radioimmunoassay including radioimmunoassay, enzyme immunoassay, fluorescence polarization immunoassay, nephelometric assay, and the like.
- enzyme immunoassay enzyme immunoa
- a reactant charge was prepared, including 558 g . of dodecenylsuccinic anhydride and 192 gm. of propylene glycol (which includes a 20% excess over the stoichometric requirement for the reaction, to serve as the reaction medium), placed in a one liter reaction vessel equipped with a stirrer, fused and heated gradually to a final temperature of 225-230°C. Water of reaction was collected from a temperature of approximately 190°C. The diol component was retained in the reaction mixture by the action of a Vigreaux fractionating column. The rate of temperature increase was regulated so that the still head temperature did not exceed 110°C during the initial condensation.
- Example 2 The same general procedure described in Example 1 was followed in preparing a polyester from a reactant charge comprising 314 gm. of dodecenylsuccinic anhydride, 221 gm. of azelaic acid and 215 gm. of propylene glycol, except that one half the amount of the DBTDA catalyst was used and vacuum distillation proceeded for an additional 2 hours.
- the resultant product had an acid value of 1.8, a hydroxyl value of 9.5, 210°F kinematic viscosity of 2554.
- a polyester was prepared from a reactant charge comprising 335 gm. linoleic acid-acrylic acid adduct, 661 gm. azelaic acid, 405 gm. neopentyl glycol and 99 gm. propylene glycol.
- the reaction was carried out in a 2 liter reaction vessel equipped with a stirrer and a Vigreaux fractionating column, following the same general reaction conditions set forth in Example 1, above, except that vacuum distillation was performed for approximately 10 hrs. overall.
- the polyester obtained from this reaction had an acid value of 0.73, an hydroxyl value of 18.6, 210°F kinematic viscosity of 1912 and density at room temperature of 1.0348.
- Example 4 A polyester was prepared from a reactant charge including 229 gm. linoleic acid-acrylic acid adduct, 393 gm. of a mixture of dicarboxylic acid dimethyl esters, including 75% dimethyl glutarate, 24% dimethyl adipate and 1% dimethyl succinate, 390 gm. oleic dimer acid, 352 gm. neopentyl glycol and 86 gm. propylene glycol. The reaction was run in a 2 liter reaction vessel equipped as described in Example 3. The reaction conditions described in Example 1 were followed for the most part with certain variations.
- the catalyst (DBTDA) was introduced at the outset of the reaction, and in an amount of 0.02%, based on the total weight of the reactant charge.
- the heating rate was adjusted so that the head temperature did not exceed 90°C until an amount of distillate corresponding approximately to the predicted weight of ethanol was collected.
- the upper limit of the reaction temperature was approximately 225°C. Stripping of the reaction medium to the desired viscosity was carried out essentially as described in Example 1, above.
- the polyester obtained from the reaction had an acid value of 1.1, an hydroxyl value of 14.1, 210°F kinematic viscosity of 1972 and density at room temperature of 1.0202.
- a reactant charge was prepared including 508 gm . dodecenylsuccinic anhydride 1116 gm. oleic acid dimer , 1123 gm. of the ester mixture described in Example 4 , 1008 gm. neopentyl glycol and 245 gm. propylene glycol .
- This charge together with 0.02% of DBTDA, was placed in a 5 liter reaction vessel equipped as described in Example 3 , and reacted following the general procedure of Example 4.
- the reaction yielded a polyester having an acid value of 0.3, an hydroxyl value of 14.1, 210°F kinematic viscosity of 2510 and density at room temperature of 1.0226.
- a polyester was prepared from a reactant charge, including 196 gm. linoleic acid-acrylic acid adduct, 193 gm. dimethyl azelate, 558 gm. of the ester mixture described in Example 4, 445 gm. neopentyl glycol and 108 gm. propylene glycol, together with 0.02% DBTDA, following the general procedure of Example 4, with the exception that the usual vacuum esterification stage to reduce free acidity proved unnecessary in this case.
- the product of the reaction had an acid value of 0.4, an hydroxyl value of 8.3, 210°F kinematic viscosity of 2256 and density at room temperature of 1.082.
- Polyesters prepared as described in the foregoing examples were evaluated for interaction with the antidepressant, imipramine (IM) and the anticonvulsant, phenobarbital (PB) , two drugs which are commonly administered under TDM. A recovery of 90% was established as a benchmark for utilization of the polyesters of the invention in TDM programs. The results of these evaluations are set forth below in Table I.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Ecology (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- External Artificial Organs (AREA)
- Polyesters Or Polycarbonates (AREA)
Abstract
A polyester is provided which facilitates the separation of blood into light and heavy phases via centrifugation in a blood collection vessel. The polyester is useful as a component of a partitioning composition formulated to have appropriate specific gravity to be positioned intermediate the light and heavy blood phases during centrifugation. A partitioning composition including a polyester of the invention provides a particular advantage in blood collection vessels used in therapeutic drug monitoring, due to the relatively low affinity between the polyester component of the composition and commonly monitored classes of drugs.
Description
r „ , . ι LY PARTITIONING COMPOSITIONS
BACKGROUND OF THE INVENTION
The present invention relates to polyesters useful for facilitating the separation of blood serum 5 or plasma from the cellular portion of blood. The polyesters of the invention are conveniently formulated into a partitioning composition for use in a blood collection vessel in which the blood sample is subjected to centri ugation until the cellular portion 10 and serum or plasma are completely separated. The physical and chemical properties of the partitioning composition are such that a continuous, integral seal is provided between the separated blood phases, thereby maintaining separation of the phases after 15 centrifugation and simplifying removal of the serum or plasma from the blood collection vessel.
The high volume testing of blood components in hospitals and clinics has led to the development of various devices to simplify the collection of blood 20 samples and preparation of the samples for analysis. Typically, whole blood is collected in an evacuated, elongated glass tube that is permanently closed at one end and sealed at the other end by a rubber stopper having a diaphragm which is penetrated by the 25 double-tipped cannula used to draw the patient's blood. After the desired quantity of blood is collected, the collection vessel is subjected to centrifugation to yield two distinct phases comprising the cellular portion of the blood (heavy phase) and the blood serum 30 or plasma (light phase). The light phase is typically removed from the collection vessel, e.g., via pipette or decantation, for testing.
It has been proposed heretofore to provide manufactured, seal-forming members, e.g., resilient
pistons, spools, discs and the like, in blood collection vessels to serve as mechanical barriers between the two separated phases. Because of the high cost of manufacturing such devices to the close tolerances required to provide a functional seal, they have been supplanted by fluid sealant compositions.
Fluid sealant compositions are formulated to have a specific gravity intermediate the two blood phases sought to be separated, so as to provide a partition a the interface between the cellular and serum phases. Such compositions typically include a polymer base material, one or more additives for adjusting the specific gravity and viscosity of the resultant composition, and optionally, a network former. Representative prior art fluid sealant compositions include: styrene beads coated with an anti-coagulent (U.S. Patent 3,464,890); silicone fluid having silica dispersed therein (U.S. Patent 3,780,935); a homogenous, hydrophobic copolyester including a suitable filler, e.g., silica (U.S. Patents 4,101,422 and 4,148,764); a liquid -olefin-dialkylmaleate, together with an aliphatic amine derivative of smectite clay or powdered silica (U.S. Patent 4,310,430); the reaction product of a silicone fluid with a silica filler and a network former (U.S. Patent 4,386,003); and a mixture of compatible viscous liquids, e.g., epoxidized vegetable oil and chlorinated polybutene, and a thixotropy- imparting agent, e.g., powdered silica (U.S. Patent 4,534,798). Ideally, a commercially useful blood partitioning composition should maintain uniform physical and chemical properties for extended time periods prior to use, as well as during transportation and processing of blood samples, readily form a stable partition under normal centrifugation conditions and be relatively inert or unreactive toward the substance(s)
in the blood whose presence or concentration is to be determined.
Inertness to substances sought to be determined is a particular concern when blood collection vessels are used for therapeutic drug monitoring (TDM) , which is assuming an increasingly important role in drug treatment strategies. TDM enables the administration of drugs in the appropriate therapeutic ranges, established through the accumulated experience of clinicians, and consequently reduces the number of patients receiving dosage levels that are either below detection limits or toxic. Administration of drugs under TDM allows one to take into account such factors as drug tolerance developed with passage of time, presence of multiple physical disorders and synergistic or antagonistic interactions with other therapeutic agents. Among the drugs recommended for administration under TDM are those having dangerous toxicity with poorly defined clinical endpoint, steep dose-response curve, narrow therapeutic range, considerable inter-individual pharmacokinetic variability or non-linear pharmacokinetics, as well as those used in long term therapy or in the treatment of life-threatening diseases. By way of example, the evaluation of blood levels of a number of tricyclic antidepressant compounds, such as imipramine or desipra ine, in relation to an empirically established therapeutic range is reported to be particularly useful in the treatment of seemingly drug-refractive depression. TDM is likewise used to monitor the dosage of anticonvulsant drugs, such as phenytoin and phenobarbital which are administered in the treatment of epilepsy, antitumor drugs, such as methotrexate, and other more commonly prescribed drugs, including, but not limited to digoxin, lidocaine, pentobarbital and theophylline.
Reports of recent studies on the effect of blood partitioning compositions on drug concentrations in serum and plasma indicate that care must be taken in the selection of polymeric materials which come into contact with the blood samples obtained for drug assay. See, for example, P. Orsulak et al., Therapeutic Drug Monitoring, 6:444-48 (1984) and Y. Bergqvist et al. Clin. Chem. , 30:465-66 (1984). The results of these studies show that the blood partitioning compositions provided in blood collection vessels may account for reduced serum or plasma values, as a result of drug absorption by one or more components of the composition. The reported decreases in measured drug concentrations appears to be time-dependent. One report concludes that the observed decreases in drug concentrations may effectively be reduced by minimizing the interval between collection and processing. Another report recommends that blood samples be transported to the laboratory as soon as possible, with processing occurring within 4 hours. A commercially useful blood collection vessel, however, must produce accurate test results, taking into account routine clinical practices in large institutions, where collection, transportation and processing of blood samples may realistically take anywhere from about 1-72 hours.
SUMMARY OF THE INVENTION
In accordance with the present invention, it has been discovered that certain highly hydrophobic polyesters satisfy the above-noted criteria for incorporation in a clinically useful blood partitioning composition. The polyesters of the invention comprise, as their reactive components, at least one diol and at least one dicarboxylic acid, including a first dicarboxylic acid containing from 15-36 carbom atoms, which comprises from 10-100
equivalent percent of the total acid component equivalents, and a second dicarboxylic acid, selected from the group of short chain dicarboxylic acids and polymeric fatty acids, which comprises up to 90 equivalent percent of the total acid component equivalents. The resultant polyester product is a viscous liquid having a density at room temperature (25°C) in the range of 1.01-1.09.
Particularly useful polyester products have been obtained from the reaction of dodecenylsuccinic acid with propylene glycol and from the reaction of linoleic acid-acrylic acid adduct, as the first dicarboxylic acid, and an acid selected from the group of succinic acid, glutaric, adipic acid, azelaic acid, oleic dimer acid, or a mixture thereof, as the second dicarboxylic acid, with a mixture of neopentyl glycol, and propylene glycol.
The polyesters of the invention are readily formulated together with other ingredients, typically a suitable filler and compatible surfactant, into functional blood partitioning compositions. The density of the finished blood partitioning composition is controlled within prescribed limits, so that during centrifugation the composition becomes stably positioned at the interface between the serum or plasma phase and heavier cellular phase and, when centrifugation is terminated, forms a continuous integral barrier within the blood collection vessel to prevent the two phases from recombining or mixing, especially when decanting or pipetting the serum or plasma. The blood partitioning compositions of the invention are advantageously employed in small amounts, on the order of 1-5 gm. , in a 10 ml blood collection vessel of the type previously described which are then ready for use in blood sampling and analysis in the usual way. The polyester-based blood partitioning compositions of the invention are
especially suited for use in TDM procedures, displaying negligible interaction with commonly monitored therapeutic agents.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to polyesters derived from one or more relatively long-chain dicarboxylic acids, having 15-36 carbon atoms, optionally, a second dicarboxylic acid, selected from the group of short chain dicarboxylic acids and polymer fatty acids, and a diol. When the reactive components of the polyesters are combined in the prescribed ratios and esterified using conventional esterification techniques, polyester products are obtained having molecular weights from about 3,000 to about 12,000 (number average, as determined by gel permeation chromatography) . The polyesters of the invention are produced in the form of viscous liquids, having a density at room temperature in the range of 1.01-1.09. Particularly notable among the properties of these polyesters is their inertness, making them especially useful in TDM programs. The polyesters of the invention are also highly hydrophobic, exhibiting neglible water solubility. The physical and chemical properties of these polyesters are uniformly maintained over extended periods prior to use, as well as during transportation and processing of blood samples. Among the other notable characteristics of these polyesters is the ability to undergo ultracentrifugation for up to 1 hour at up to 1500 G (G being the ratio of centrifugal acceleration to acceleration of gravity) , without any detectable adverse effect.
The polyesters of the invention are further characterized by having an acid value of 2 or less, an hydroxyl value of 23 or less and a 210°F kinematic viscosity of about 1700-4000 centistokes.
_ ? _
Polyesters having the above-described properties are especially useful as blood partitioning agents in blood collection vessels where they provide a continuous integral barrier or seal between the serum and clot portions of blood. In other words, the polyester completely partitions the separated phases so that the serum and cellular or clot portions are no longer in contact at any point, forming a unitary seal which firmly adheres to the inner surface of the blood collection vessel. By forming a continuous, integral barrier in this way, it is possible to easily remove the serum or plasma portion by decanting or pipetting, with the clot portion remaining undisturbed in the collection vessel. The reactive components of the polyesters of the invention include at least one dicarboxylic acid, including a first dicarboxylic acid containing 15-36 carbon atoms, a second dicarboxylic acid, selected from the group of short-chain dicarboxylic acids and polymeric fatty acids, and at least one diol. The first dicarboxylic acid is preferably selected from the group of polyalkenylsuccinic acids, adducts of unsaturated monocarboxylic acids or a mixture thereof. The first dicarboxylic acid may be the exclusive constituent of the acid component of the polyester. Alternatively, the second dicarboxylic acid may optionally be added to the acid component.
Short-chain dicarboxylic acids suitable for preparing the polyesters of the invention are saturated aliphatic acids having 4-12 carbon atoms. More preferably, these acids have from 4-9 carbon atoms and are essentially straight-chain acids. Representative short chain dicarboxylic acids include succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, undecanedoic acid and dodecanedoic acid. Mixtures of
_ fl _
two or more of such short-chain dicarboxylic acids may be used, if desired.
The polymeric fatty acids which may be used to prepare the polyesters of the invention are obtained by the polymerization of olefinically unsaturated monocarboxylic acids having from 16-20 carbon atoms, such as pal itoleic acid, oleic acid, linoleic acid, linolenic acid and the like. Polymeric fatty acids and processes for their production are well known. See, for example, U.S. Patent Nos. 2,793,219 and 2,955,121. Polymeric fatty acids useful in the practice of this invention preferably will have as their principal component C-36 dimer acid. Such C-36 dicarboxylic acids are obtained by the dimerization of two moles of a C-18 unsaturated monocarboxylic acid, such as oleic acid or linoleic acid, or mixtures thereof, e.g., tall oil fatty acids. These products typically contain 75% by weight or more of C-36 dimer acid and have an acid value in the range of 180-215, saponification value in the range of 190-215 and neutral equivalent from 265-310. The dimer acids may be hydrogenated prior to use. To increase the C-36 dimer content and reduce the amount of by-product acids, including unreacted monobasic acid, tri er and higher polymer acids, the polymeric fatty acid may be molecularly distilled or otherwise fractionated.
The first dicarboxylic acid comprises from 10-100 equivalent percent of the total acid component equivalents; whereas the second dicarboxylic acid, when used, may comprise up to 90 equivalent percent of the total acid component equivalents. The equivalent percent of short-chain dicarboxylic acid(s) in the second dicarboxylic acid component will generally range from about 80 to about 100 equivalent percent of the total acid components provided by the second dicarboxylic acid. The polymeric fatty acid, when used, will generally comprise up to about 20
6 . Q .
equivalent percent of the total acid component equivalents provided by the second dicarboxylic acid. It will be apparent to those skilled in the art that the various art-recognized equivalents of the aforementioned dicarboxylic acids, including anhydrides and lower alkyl esters thereof, may be employed in preparing the polyesters of the invention.
Accordingly, as used herein, the term "acid" is intended to encompass such acid derivatives. Methyl esters are particularly advantageous for the preparation of the polyesters described herein.
Mixtures of acids, anhydrides and esters may also be reacted to obtain the desired product.
Suitable diols which may be reacted with the above-described dicarboxylic acid(s) to yield the polyesters of the invention include diols of the formula:
HO(- "Cf-(CR5R6)x-C-0-)nH R2 R in which R^, R2, R3 and R are independently selected from the group consisting of hydrogen and an alkyl having 1-4 carbon atoms, n = 1-4 and x = 0-4. Representative diols falling within the foregoing formula include neopentyl glycol, propylene glycol, diethylene glycol, triethylene glycol, 3-methyl-l,5- pentane diol, 1,2 propane diol, 1,3-butane diol, 1,2-butane diol, 1,2-pentane diol, 1,3-pentane diol, 1,4-pentane diol and the like. The preferred diols contain from 3-5 carbon atoms, with particularly useful polyesters products being obtained using neopentyl glycol, propylene glycol, triethylene glycol, or mixtures thereof. In a particularly preferred embodiment of the invention, in which a
mixture of neopentyl glycol and propylene glycol is used, the amount of neopentyl glycol comprises about 70 to about 95 equivalent percent, and the amount of propylene glycol comprises about 5 to about 30 equivalent percent of the total diol component equivalents.
Conventional esterification procedures and equipment are used to obtain the polyester of the invention. The reactive components are normally added to the reaction vessel as a unit charge and the reaction mixture is then heated with agitation at a temperature from about 150-250°C for a period of time sufficient to substantially complete the esterification reaction. The reaction may be driven to completion by application of vacuum (typically 1-5 mm Hg absolute at 200-250°C) until the desired properties are obtained. Vacuum distillation removes the final traces of water, any excess reactants and small amounts of other volatile materials present in the reaction mixture.
If an improvement in color is desired, the polyester may be bleached by any of the well known and acceptable bleaching methods, e.g., using hydrogen peroxide or chlorite. Alternatively, the polyester may be decolorized by filtering through a filter aid, charcoal or bleaching clay.
The rate of esterification may be enhanced by the use of known esterification catalysts. Suitable esterification catalysts for enhancing the rate of esterification of free carboxyl groups include phosphoric acid, sulfuric acid, toluenesulfonic acid, methane sulfonic acid, and the like. The amount of such catalyst may vary widely, but most often will be in an amount from about 0.1% to about 0.5% by weight, based on the total reactant charge. Catalysts useful for effecting ester interchange include dibutyltin diacetate, stannous oxalate, dibutyltin oxide,
tetrabutyl titanate, zinc acetate and the like. These catalysts are generally employed in an amount ranging from about .01% to .05% by weight, based on the total resistant charge. When such catalysts are used, it is not necessary that the catalyst be present throughout the entire reaction. It is sometimes advantageous in order to obtain products having good color and relatively low acid value, on the order of 2 mg KOH/gm, or less, to add the catalyst during the final stages of the reaction. Upon completion of the reaction, the catalyst may be deactivated and removed by filtering or other conventional means.
Inert diluents, such as benzene, toluene, xylene and the like may be employed for the reaction, however, the use of diluents is not necessary. It is generally considered desirable to conduct the reaction without diluents since the resultant polyester can be directly used as it is obtained from the reaction vessel. A small excess (based on the equivalents of acid present) of the diol component may be used if desired. The excess diol serves as the reaction medium and reduces the viscosity of the reaction mixture. The excess diol is distilled off as the esterification is carried to completion and may be recycled to the reactor if desired. Generally, about 20% by weight excess diol, based on the total weight of the diol component, will suffice. The more volatile glycols are commonly used for this purpose.
A particularly useful blood partitioning agent is obtained by reacting substantially stoichiometric amounts of (i) linoleic acid-acrylic acid adduct, having 21 carbon atoms, as the first dicarboxylic acid component, a second dicarboxylic acid comprising (ii) oleic dimer acid and (iii) a mixture of dimethyl succinate, dimethyl glutarate, and dimethyl adipate, with a diol component comprising neopentyl glycol and propylene glycol. The equivalents ratio of the
three dicarboxylic acid components is 1:1:3.55, with the relative approximate weight percentages of the esters in the ester mixture being 1% dimethyl succinate, 75% dimethyl glutarate and 24% dimethyl adipate. The equivalents ratio of neopentyl glycol to propylene glycol ranges from about 0.75:0.25 to about 0.90:0.10.
Another particularly useful polyester product is obtained from the reaction of essentially stoichiometric amounts of dodecenylsuccinic acid and propylene glycol.
The source of the acids or acid derivatives and the manner by which the dicarboxylic acid blends are prepared, in those embodiments where such blends are used, is of no consequence so long as the resulting blend contains the specified acids or acid derivatives in the required ratios. Thus, dicarboxylic acid or acid derivative blends may be obtained by mixing the individual acid components. On the other hand, mixtures of acid obtained as by-products from various manufacturing operations and which contain one or more of the necessary acid components may be advantageously utilized. For example, mixed dimethyl esters of succinic, glutaric and adipic acids may be obtained as a co-product from the manufacture of adipic acid and may be conveniently blended with any other acid, e.g., oleic dimer acid selected for inclusion in the polyester of the invention.
Preparation of blood partitioning compositions using the polyesters of the invention may be carried out in the manner described in commonly owned U.S. Patents Nos. 4,101,422 and 4,148,764, the entire disclosures of which are incorporated by reference in the present specification, as if set forth herein in full.
Determination of the extent of interaction between the polyesters of the invention and commonly
monitored drugs may be carried out using well known recovery experiments and drug measurement techniques, such as, gas chromatography, gas-liquid chromatography, high-performance liquid chromatography, thin layer chromatography or immunoassay techniques, including radioimmunoassay, enzyme immunoassay, fluorescence polarization immunoassay, nephelometric assay, and the like. A variety of suitable procedures are reported in the literature. See, for example, Bergqvist et al., supra Such determinations may be carried out using human serum, or commercially available bovine serum, if desired.
The following examples are presented to illustrate the invention more fully, and are not intended, nor are they to be construed, as a limitation of the scope of the invention. In the examples, all percentages are on a weight basis unless otherwise indicated. Example 1
A reactant charge was prepared, including 558 g . of dodecenylsuccinic anhydride and 192 gm. of propylene glycol (which includes a 20% excess over the stoichometric requirement for the reaction, to serve as the reaction medium), placed in a one liter reaction vessel equipped with a stirrer, fused and heated gradually to a final temperature of 225-230°C. Water of reaction was collected from a temperature of approximately 190°C. The diol component was retained in the reaction mixture by the action of a Vigreaux fractionating column. The rate of temperature increase was regulated so that the still head temperature did not exceed 110°C during the initial condensation. When the rate of water evolution diminished sharply, i.e., when about 85% of the expected distillate had been collected, a partial vacuum was applied to complete the conversion of acid
groups present to esters (about 28 inches vacuum at 225°C) . The vacuum esterification stage required about 3-4 hours. At this point, an interchange catalyst was introduced (0.02% dibutyltin diacetate (DBTDA) based on the total reactant charge), the fractionating column was removed, and relatively high vacuum applied (approximately 1-2 mm Hg). Distillation of volatile diol proceeded slowly until the target viscosity was achieved, which required approximately 6 hours. The product was filtered through a coarse screen. The polyester recovered had an acid value of 3.0, an hydroxyl value of 22.4, 210°F kinematic viscosity of 1978.
Example 2
The same general procedure described in Example 1 was followed in preparing a polyester from a reactant charge comprising 314 gm. of dodecenylsuccinic anhydride, 221 gm. of azelaic acid and 215 gm. of propylene glycol, except that one half the amount of the DBTDA catalyst was used and vacuum distillation proceeded for an additional 2 hours. The resultant product had an acid value of 1.8, a hydroxyl value of 9.5, 210°F kinematic viscosity of 2554.
Example 3
A polyester was prepared from a reactant charge comprising 335 gm. linoleic acid-acrylic acid adduct, 661 gm. azelaic acid, 405 gm. neopentyl glycol and 99 gm. propylene glycol. The reaction was carried out in a 2 liter reaction vessel equipped with a stirrer and a Vigreaux fractionating column, following the same general reaction conditions set forth in Example 1, above, except that vacuum distillation was performed for approximately 10 hrs. overall. The polyester obtained from this reaction had an acid value of 0.73,
an hydroxyl value of 18.6, 210°F kinematic viscosity of 1912 and density at room temperature of 1.0348.
Example 4 A polyester was prepared from a reactant charge including 229 gm. linoleic acid-acrylic acid adduct, 393 gm. of a mixture of dicarboxylic acid dimethyl esters, including 75% dimethyl glutarate, 24% dimethyl adipate and 1% dimethyl succinate, 390 gm. oleic dimer acid, 352 gm. neopentyl glycol and 86 gm. propylene glycol. The reaction was run in a 2 liter reaction vessel equipped as described in Example 3. The reaction conditions described in Example 1 were followed for the most part with certain variations. Specifically, the catalyst (DBTDA) was introduced at the outset of the reaction, and in an amount of 0.02%, based on the total weight of the reactant charge. In addition, the heating rate was adjusted so that the head temperature did not exceed 90°C until an amount of distillate corresponding approximately to the predicted weight of ethanol was collected. The upper limit of the reaction temperature was approximately 225°C. Stripping of the reaction medium to the desired viscosity was carried out essentially as described in Example 1, above. The polyester obtained from the reaction had an acid value of 1.1, an hydroxyl value of 14.1, 210°F kinematic viscosity of 1972 and density at room temperature of 1.0202.
Example 5
A reactant charge was prepared including 508 gm . dodecenylsuccinic anhydride 1116 gm. oleic acid dimer , 1123 gm. of the ester mixture described in Example 4 , 1008 gm. neopentyl glycol and 245 gm. propylene glycol . This charge , together with 0.02% of DBTDA, was placed in a 5 liter reaction vessel equipped as described in Example 3 , and reacted following the general procedure
of Example 4. The reaction yielded a polyester having an acid value of 0.3, an hydroxyl value of 14.1, 210°F kinematic viscosity of 2510 and density at room temperature of 1.0226.
Example 6
A polyester was prepared from a reactant charge, including 196 gm. linoleic acid-acrylic acid adduct, 193 gm. dimethyl azelate, 558 gm. of the ester mixture described in Example 4, 445 gm. neopentyl glycol and 108 gm. propylene glycol, together with 0.02% DBTDA, following the general procedure of Example 4, with the exception that the usual vacuum esterification stage to reduce free acidity proved unnecessary in this case. The product of the reaction had an acid value of 0.4, an hydroxyl value of 8.3, 210°F kinematic viscosity of 2256 and density at room temperature of 1.082.
Polyesters prepared as described in the foregoing examples were evaluated for interaction with the antidepressant, imipramine (IM) and the anticonvulsant, phenobarbital (PB) , two drugs which are commonly administered under TDM. A recovery of 90% was established as a benchmark for utilization of the polyesters of the invention in TDM programs. The results of these evaluations are set forth below in Table I.
All of the recovery values reported above were obtained using commercially available bovine serum. Experience has shown that higher recovery values (up to about 2% higher) are obtainable with human serum. While the present invention has been described and exemplified above in terms of certain preferred embodiments, various other embodiments may be apparent to those skilled in the art. Accordingly, the invention is not limited to the embodiments specifically described and exemplified, but variations and modifications may be made therein and thereto without departing from the spirit of the invention, the full scope of which is delineated by the following claims.
Claims
1. A polyester, comprising, as its reactive components, at least one diol and at least one dicarboxylic acid, including a first dicarboxylic acid containing 15-36 carbon atoms, which comprises from 10 to 100 equivalent percent of the total acid component equivalents, and a second dicarboxylic acid selected from the group consisting of short chain acids and polymeric fatty acids, said second dicarboxylic acid comprising up to 90 equivalent percent of the total acid component equivalents, said polyester being in the form of a viscous liquid and having a density at room temperature in the range of 1.01-1.09.
2. A polyester in accordance with claim 1, wherein said first dicarboxylic acid is selected from the group consisting of a polyalkenylsuccinic acid, an adduct of unsaturated monocarboxylic acids, or a mixture thereof.
3. A polyester in accordance with claim 1, wherein said diol has the general formula
RT. R3
I I
HO(-C-(CR5R6)χ-C-0-)nH
I I
R2 R4
in which Rι_, R2, R3, R4, R5 and Rg are independently selected from the group consisting of hydrogen and alkyl having 1-4 carbon atoms, n = 1-4 and x = 0-4.
4. A polyester in accordance with claim 2, wherein said diol is selected from the group consisting of propylene glycol, neopentyl glycol, triethylene glycol or a mixture thereof.
5. A polyester in accordance with wherein said second dicarboxylic acid is selected from the group consisting of succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, undecanedioic acid, dodecanedioic acid, oleic dimer acid, or mixtures thereof.
6. A polyester in accordance with claim 2, comprising as its reactive components a first dicarboxylic acid selected from the group consisting of dodecenylsuccinic acid, linoleic acid-acrylic acid adduct, or a mixture thereof, a diol selected from the group consisting of propylene glycol, neopentyl glycol, triethylene glycol or a mixture of two or more of said diols and a second dicarboxylic acid selected from the group consisting of succinic acid, glutaric acid, adipic acid, azelaic acid, oleic dimer acid or a mixture of two or more of said second dicarboxylic acids.
7. A polyester in accordance with claim 1 having an acid value of 2 or less, an hydroxyl value of 23 or less and a 210°F kinematic viscosity of about 1700-4000 centistokes.
8. A polyester in accordance with claim 1, the reactive components of which consist essentially of substantially stoichiometric amounts of dodecenylsuccinic acid and propylene glycol.
9. A polyester in accordance with claim 1, the reactive components of which consist essentially of substantially stoichiometric amounts of:
(a) linoleic acid - acrylic acid adduct;
(b) oleic dimer acid;
(c) a mixture of dimethyl succinate (DMS), dimethyl glutarate (DMG) and dimethyl adipate (DMA);
(d) neopentyl glycol; (e) propylene glycol, the equivalents ratio of (a) to (b) to (c) being 1:1:3.55, the relative weight percentages of said esters in said mixture being about 1% DMS, about 75% DMG and about 24% DMA and the equivalents ratio of (d):(e) being from about 0.75:0.25 to about 0.90:0.10.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44491789A | 1989-12-04 | 1989-12-04 | |
US444,917 | 1989-12-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1991008246A2 true WO1991008246A2 (en) | 1991-06-13 |
WO1991008246A3 WO1991008246A3 (en) | 1991-07-11 |
Family
ID=23766883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/006967 WO1991008246A2 (en) | 1989-12-04 | 1990-11-29 | Polyesters for use in blood partitioning compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1991008246A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0520184A1 (en) * | 1991-06-25 | 1992-12-30 | Nissho Corporation | Blood separation means |
WO1993004105A1 (en) * | 1991-08-15 | 1993-03-04 | Henkel Corporation | Polyesters for use in blood partitioning compositions |
EP0537507A1 (en) * | 1991-10-16 | 1993-04-21 | Nissho Corporation | Blood separating composition |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB685649A (en) * | 1949-05-02 | 1953-01-07 | Bataafsche Petroleum | A process for the preparation of polyesters, the polyesters so prepared and plastic compositions containing the polyesters |
US4101422A (en) * | 1977-05-11 | 1978-07-18 | Emery Industries, Inc. | Copolyesters useful in blood separation assemblies |
US4480087A (en) * | 1983-06-30 | 1984-10-30 | Eastman Kodak Company | Polyester waxes based on alkylsuccinic anhydride or alkenylsuccinic anhydride |
-
1990
- 1990-11-29 WO PCT/US1990/006967 patent/WO1991008246A2/en unknown
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0520184A1 (en) * | 1991-06-25 | 1992-12-30 | Nissho Corporation | Blood separation means |
US5354838A (en) * | 1991-06-25 | 1994-10-11 | Nissho Corporation | Blood separation composition |
WO1993004105A1 (en) * | 1991-08-15 | 1993-03-04 | Henkel Corporation | Polyesters for use in blood partitioning compositions |
EP0537507A1 (en) * | 1991-10-16 | 1993-04-21 | Nissho Corporation | Blood separating composition |
US5527843A (en) * | 1991-10-16 | 1996-06-18 | Nissho Corporation | Blood separating composition |
Also Published As
Publication number | Publication date |
---|---|
WO1991008246A3 (en) | 1991-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5124434A (en) | Polyesters for use in blood partitioning compositions | |
US6248844B1 (en) | Method of partitioning blood using polyesters | |
US5556557A (en) | Method of partitioning blood using polyesters | |
US5731391A (en) | Fluid composition for physiological separations with enhanced resistance to inward migration of substances requiring accurate dosage monitoring | |
EP1246678B1 (en) | Physiological fluid separation vehicles having improved resistance to inward migration of therapeutic agents | |
JP2003533455A (en) | Polymerizable dispersant | |
AU649828B2 (en) | Serum and plasma separating compositions and blood testing containers | |
EP0934350B1 (en) | Branched polyesters | |
WO1991008246A2 (en) | Polyesters for use in blood partitioning compositions | |
EP0520184B1 (en) | Blood separation means | |
JP2001505939A (en) | Branching polyester | |
JP2830139B2 (en) | Blood separation agent | |
US3824256A (en) | Purification of alpha,alpha-disubstituted-beta-propiolactones | |
JP2841399B2 (en) | Liquid separating agent | |
JPH06220135A (en) | Allyl ether compound-based copolymer and blood separating agent containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
NENP | Non-entry into the national phase |
Ref country code: CA |